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NO-sensitive guanylyl cyclases (soluble guanylyl cyclase,
sGC) are among the key regulators of intracellular cGMP
concentration. The mechanisms underlying NO-mediated
activation of sGC are quite well understood, however, lit-
tle is known about the fine-tuning of sGC activity through
alternative mechanisms such as protein phosphorylation.
Several reports have demonstrated the reversible phos-
phorylation of sGC on serine/threonine residues, and it
has been speculated, though not experimentally proven,
that sGC might also be phosphorylated on tyrosine resi-
dues. Using broad-spectrum phosphatase inhibitors we
were able to demonstrate tyrosine phosphorylation at
Tyr192 of the β1 subunit of human sGC in COS1 cells.
This residue forms part of a sequence segment (YEDL)
representing a preferential binding site for SH2 domains
of Src-like kinases. Pull-down assays and co-immunopre-
cipitation experiments showed that Src can indeed bind
via its SH2 domain to pTyr192 of β1 indicating that tyro-
sine phosphorylation of sGC may be followed by recruit-
ment of Src-like kinases to the phosphorylated β1 subunit.
In support of this hypothesis, immunofluorescence stud-
ies showed a colocalization of overexpressed sGC and Src
at the plasma membrane of COS1 and Hela cells.
Together, our results point to an unexpected crosstalk
between tyrosine kinase pathway(s) and the NO/cGMP
signalling cascade which may result in translocation of the
predominantly cytosolic sGC to the cytosolic face of the
plasma membrane.
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